Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest

Twelve Contest Winners Announced at Annual ASRM Meeting

Oct 15, 2007, 01:00 ET from Ferring Pharmaceuticals

    WASHINGTON, Oct. 15 /PRNewswire/ -- Twelve lucky families won Ferring
 Pharmaceuticals' national 2007 My Little Miracle Essay Contest for their
 dramatic, heart-warming stories of the births of their 'little miracles,'
 children born with the help of Ferring's family of fertility treatments.
 The fourth annual contest celebrated the birth of children made possible
 through Ferring's BRAVELLE(R) (urofollitropin for injection, purified)
 and/or MENOPUR(R) (menotropins for injection, USP). The winners were
 announced at the 63rd annual meeting of the American Society for
 Reproductive Medicine (ASRM) in Washington, D.C., October 13-17, 2007.
     The grand prize winner, Victoria Knapp of Pasadena, CA will receive
 $10,000 for an education fund for her seven-month-old son, Hendrick,
 conceived after enduring severe complications from fibroid tumors which
 ultimately caused her inability to maintain a pregnancy. Despite extensive
 surgeries and lengthy recovery time, the couple was determined to have a
 child in spite of medical barriers. Thanks to the wonder of fertility
 treatments, Victoria and her husband Christopher are the proud parents of a
 'little miracle.'
     "Every story that we receive portrays the real life struggle that
 couples endure on their path to becoming parents, and each essay is just as
 heartwarming and inspirational as the next which makes it difficult for us
 to choose a winner," said Wayne Anderson, president, Ferring
 Pharmaceuticals. "But Victoria and Christopher's story of overcoming major
 medical issues along with their intense desire to give birth had a
 profoundly happy ending, and we are delighted that our treatments played a
 role in their success. Stories like these fuel our ongoing commitment to
 providing the most effective and patient-friendly treatments for families
 struggling to achieve parenthood."
     "I can't believe my story was chosen and I'm the grand prize winner,"
 said Victoria. "My heart goes out to the many women who have endured the
 same struggles as me to conceive a child. I feel blessed to have had a
 child and now we have a head start on his education, thanks to this
 wonderful program from Ferring."
     Victoria Knapp's Story
     Victoria's story chronicles the defining moments of her life, starting
 with her adoption at birth that led to an understanding at an early age
 that families are created in different ways. The tragic death of her
 brother at age 15 was another such defining moment. A successful career
 meant that Victoria married later in life and delayed starting a family.
 After multiple pregnancy losses, Victoria's dream of ever carrying a child
 was shattered when her doctor told her that fibroid tumors in her uterus
 were standing in the way of maintaining a pregnancy. Her doctor also said
 that she should consider a hysterectomy and a surrogate, but Victoria was
 unwavering in her commitment to have children. After two years of
 considering her options and many surgeries to remove the fibroids, Victoria
 consulted with Bradford Kolb, M.D. at Huntington Reproductive Center (HRC)
 in Pasadena, CA. With the help of Dr. Kolb, Victoria decided to undergo in
 vitro fertilization (IVF) treatment and was prescribed BRAVELLE and MENOPUR
 and responded beautifully to the medication. Two blastocysts were
 transferred into Victoria's uterus and on March 6, 2007, after a
 challenging pregnancy, Victoria and Christopher welcomed their son Hendrick
 Thomas into their family. In her essay, Victoria speaks of the infinite joy
 that the birth of Hendrick has brought her:
     "On March 6, 2007, at 38 weeks and after five grueling months of bed rest,
     Hendrick Thomas (Thomas after my brother) was born weighing 8 lbs. 9 oz.
     and measuring 22 inches.  It was defining moment number five - the
     greatest, most humbling, deeply fulfilling, and worth-the-wait moment of
     "I am so happy to have contributed to Victoria and Christopher's dream
 of becoming parents," said Dr. Kolb. "Although there were some
 uncertainties along the way, the end result was well worth the wait - a
 beautiful baby boy and a substantial start to his college education. We at
 HRC are proud to be a part of Victoria's 'little miracle'."
     Other Winners
     Sarah Cherovsky, of Kewaunee, MI, will receive $2,500 for an education
 fund for her 10-month-old daughter, Erin. Ten honorable mention winners
 from around the country will each receive a $500 education fund.
     BRAVELLE and MENOPUR, like all gonadotropins, are potent substances
 capable of causing mild to severe adverse reactions, including OHSS
 (incidence of 6.0% and 3.8% respectively), with or without pulmonary or
 vascular complications, in women undergoing therapy for infertility.
     The treatments are marketed by Ferring Pharmaceuticals Inc., a world
 leader in naturally occurring protein hormones. Only physicians thoroughly
 familiar with infertility treatment, including the risk of multiple births
 and adverse reactions, should prescribe these medications. Like other
 products for ovarian stimulation, treatment with BRAVELLE and/or MENOPUR
 may result in multiple gestations.
     About Ferring Pharmaceuticals
     Ferring Pharmaceuticals, part of the Ferring Group, a privately owned,
 international pharmaceutical company, manufactures and markets the largest
 family of fertility treatments of any manufacturer in the U.S. The Company
 markets BRAVELLE, MENOPUR, REPRONEX(R) (menotropins for injection, USP),
 NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R)
 (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility
 specialists and their patients. Ferring also offers the Q.CAP(TM), the
 first and only needle-free reconstitution device, for use with its
 fertility treatments.
     Ferring's line of orthopaedic and urology products includes
 EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee.
 Other products include ACTHREL(R) (corticorelin ovine triflutate for
 injection) for the differential diagnosis of Cushing's syndrome and
 DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment
 of diabetes insipidus and primary nocturnal enuresis.
     The Ferring Group specializes in the research, development and
 commercialization of compounds in general and pediatric endocrinology,
 urology, gastroenterology, obstetrics/ gynecology and infertility. For more
 information, call 888-337-7464 or visit www.ferringusa.com or
     For full prescribing information for BRAVELLE(R) and MENOPUR(R), please
 contact Andrea Preston.
     CONTACT: Andrea Preston
               Kovak-Likly Communications
               (203) 762-8833 or apreston@KLCpr.com

SOURCE Ferring Pharmaceuticals